Seminal
The magazine and atlas of EU-funded researchA new publication from the web and AI team at Scott Charnley

Atlas / Spain

European Innovation Council · Running

ALA DIAGNOSTICS MS KIT Revolutionising the diagnosis of multiple Sclerosis with the first bioinformatic diagnostic kit that allows early detection with a simple blood test

Coordinator
Ala Diagnostics SL, Spain
Runs
1 February 2023 to 31 July 2025
Status
Running
EU funding
€1.4m
Total cost
€2.0m
Partners
1 organisations in 1 countries
Type
European Innovation Council
Grant agreement
190194105

What the project is doing

In the project's own words, from its summary on CORDIS.

Multiple Sclerosis affects around 700,000 people in Europe and 2.8 million worldwide. It is the most common chronic neurological disease in young adults in developed countries, and the main cause of disability after traffic accidents. Current diagnosis process takes one year (on average) which makes pharmacological treatment start late producing irreversible damage in patients and a worse prognosis. Combined with the high rate of misdiagnoses (20%), it leads to a healthcare cost of around €20 billion every year.

ALA DIAGNOSTICS is revolutionising MS diagnosis with the first MS diagnostic kit, based on our patented recombinant protein, which is the only specific and clinically validated biomarker that exists for the diagnosis of MS in blood. Our diagnostic test is fast, easy, cheap, non-invasive, suitable for early diagnosis of MS and easy to integrate into daily clinical routine.

Topics

Who is involved

OrganisationCityCountryRole
Ala Diagnostics SLMadridSpainCoordinator

Source: CORDIS, European Commission. Data of 5 Nov 2026, reused under the Commission's reuse policy. View on CORDIS · Grant DOI